CorFlow was founded on the belief that current PCI and cardiac care remains suboptimal due the fact that underlying microvascular dysfunction and obstruction is not detected and treated adequately. CorFlow believes, like much of the medical community, that the next frontier of innovation and positive impact on clinical outcomes in cardiology and beyond will come from the microvascular space. Our first solution is a system that will be the first to diagnose microvascular obstruction (MVO) in real time during PCI and serve as a treatment platform in the cath lab. There are ongoing clinical studies to demonstrate safety and efficacy so the platform remains investigational use only.